ADVA
4.11.2021 09:02:12 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that CSC – IT Center for Science, which operates the Finnish University and Research Network (FUNET), has set an industry record by transporting 800Gbit/s farther than ever before over a live network. Using the ADVA FSP 3000 TeraFlex™ CoreChannel™ , FUNET’s succeeded in transmitting data at 800Gbit/s on links exceeding 2,000km. The field trial shows how network operators can leverage new value in existing large-scale infrastructure and how FUNET can empower the Nordics’ academics and scientists to achieve even more. Harnessing 140GBd sub-carrier technology, ADVA’s new CoreChannel™ sled leverages 150GHz channel spacing, enabling TeraFlex™ to deliver the market’s longest reach for a single-channel 800Gbit/s solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005050/en/
“ADVA’s FSP 3000 TeraFlex™ CoreChannel™ at 800Gbit/s speed delivered impressive reach during our tests and was stable throughout the month-long test period when we ran it on our nationwide ADVA open line system . The new 800Gbit/s channel technology will give us more flexibility to choose optimum modulation per use case to improve spectral efficiency. And, more importantly, it maps efficiently to 400GbE client services,” said Jani Myyry, senior network specialist, CSC/FUNET. “This field trial demonstrates that our network can smoothly support future requirements and deliver even more to our users in the Finnish research and education community. It also will strengthen our confidence that the first multi-Terabit services we aim to deliver early next year together with other Nordic research and education networks can be implemented successfully.”
With the addition of the new CoreChannel™ sled , ADVA’s FSP 3000 TeraFlex™ is the industry’s most efficient high-capacity open optical terminal for all applications from metro to submarine links. Now trials in the ultra-long-haul FUNET transport system have proven its compatibility with deployed infrastructure and shown that it offers excellent performance in a live flexgrid network built with multi-degree ROADMs and RAMAN amplifiers. TeraFlex™ CoreChannel™ also delivers industry-leading SNR requirements, making it resilient to transmission impairments. Featuring multi-rate client support, the CoreChannel™ sled can also transport any mix of 400GbE, 100GbE and 10GbE services, protecting investment and providing complete flexibility.
“It’s fantastic to see our FSP 3000 TeraFlex™ with CoreChannel™ sled pass this major test with such flying colors. Even over the FUNET network’s longest distances, the solution surpassed expectations and showed how incredible speeds are now possible at the lowest possible cost per bit per kilometer,” commented Cornelius Fürst, director, product line management, ADVA. “One of the reasons our FSP 3000 TeraFlex™ CoreChannel™ is able to provide such great long-haul performance is that it carries data at 800Gbit/s using a 150GHz window. Not only does this help to reduce complexity and avoid stranded bandwidth, but it also makes the technology future-proof. 150GHz is the channel spacing that offers the best balance between fiber capacity and optical reach. That’s why it’s gaining traction across the industry and why our open FSP 3000 TeraFlex™ CoreChannel™ sled is ready for new innovation further down the line.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About CSC – IT Center for Science Ltd.
CSC – IT Center for Science is a Finnish center of expertise in information technology owned by the Finnish state and higher education institutions. We provide internationally high-quality ICT expert services for higher education institutions, research institutes, culture, public administration and enterprises. For more information, please visit www.csc.fi
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005050/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom